Halozyme Therapeutics, Inc. is a biopharmaceutical leader headquartered in San Diego, California, distinguished for its cutting-edge drug delivery technologies that significantly improve the effectiveness of existing treatments. Its proprietary ENHANZE® technology facilitates the development of subcutaneous formulations, thereby enhancing patient compliance and health outcomes across multiple therapeutic areas. Through strategic partnerships with prominent pharmaceutical companies, Halozyme is broadening its portfolio and solidifying its competitive stance in the biotechnology sector. With a global presence and a focus on patient-centered solutions, Halozyme is poised to meet the growing demand for innovative therapies worldwide. Show more

Location: 12390 EL CAMINO REAL, SAN DIEGO, CA, UNITED STATES, 92130, San Diego, CA, 92130, USA | Website: https://halozyme.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

8.433B

52 Wk Range

$47.50 - $79.50

Previous Close

$73.34

Open

$73.34

Volume

2,044,283

Day Range

$71.30 - $74.48

Enterprise Value

9.27B

Cash

419.7M

Avg Qtr Burn

N/A

Insider Ownership

1.14%

Institutional Own.

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
TLANDO Details TRT (Testosterone Replacement Therapy)	Approved Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tecentriq® SC w/ ENHANZE Details Solid tumor/s, Cancer	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Hylenex (hyaluronidase human injection) Details Drug absorption	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Rybrevant Faspro/Amivantamab (JNJ-61186372) (EGFR-MET Antibody) Details EGFR-Mutated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Xyosted (testosterone enanthate) Details Testosterone replacement	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Otrexup (Methotrexate) Details RA (rheumatoid arthritis) and psoriasis	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
OCREVUS ZUNOVO™ with ENHANZE® Details Multiple sclerosis	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
DARZALEX FASPRO (Daratumumab and Hyaluronidase-fihj) Details AL (Light Chain) Amyloidosis	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
DARZALEX (daratumumab) Details MM (Multiple myeloma)	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Selatogrel Details Acute myocardial infarction	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.